NYSEAMERICAN:CATX Perspective Therapeutics (CATX) Stock Price, News & Analysis → Elon’s New A.I. Device is About to Shock the World (From InvestorPlace) (Ad) Free CATX Stock Alerts 1.65 +0.01 (+0.61%) (As of 12:21 PM ET) Add Compare Share Share Today's Range1.60▼1.6750-Day Range N/A52-Week Range0.21▼1.77Volume1.65 million shsAverage Volume3.84 million shsMarket Capitalization$968.42 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipShort Interest Get Perspective Therapeutics alerts: Email Address Perspective Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.24% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.24Based on 5 Articles This WeekInsider TradingAcquiring Shares$57.41 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom -0.09 to -0.13 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.40 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Perspective Therapeutics. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.24% of the float of Perspective Therapeutics has been sold short.Short Interest Ratio / Days to CoverPerspective Therapeutics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Perspective Therapeutics has recently increased by 28.92%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPerspective Therapeutics does not currently pay a dividend.Dividend GrowthPerspective Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CATX. Previous Next 2.4 News and Social Media Coverage News SentimentPerspective Therapeutics has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Perspective Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 9 people have searched for CATX on MarketBeat in the last 30 days. This is a decrease of -47% compared to the previous 30 days.MarketBeat Follows12 people have added Perspective Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Perspective Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought 57,409,487.00 in company stock and sold 0.00 in company stock.Percentage Held by InsidersOnly 3.52% of the stock of Perspective Therapeutics is held by insiders.Percentage Held by Institutions54.66% of the stock of Perspective Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Perspective Therapeutics are expected to decrease in the coming year, from -0.09 to -0.13 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Perspective Therapeutics is -16.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Perspective Therapeutics is -16.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPerspective Therapeutics has a P/B Ratio of 6.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarAI finds its first serious applicationAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Perspective Therapeutics Stock (NYSEAMERICAN:CATX)Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.Read More CATX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CATX Stock News HeadlinesApril 30, 2024 | globenewswire.comPerspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETsApril 28, 2024 | americanbankingnews.comPerspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Sees Significant Growth in Short InterestApril 30, 2024 | InvestorPlace (Ad)Elon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” April 25, 2024 | americanbankingnews.comPerspective Therapeutics (NYSEAMERICAN:CATX) Hits New 1-Year High at $1.62April 8, 2024 | globenewswire.comPerspective Therapeutics to Participate at Upcoming April Investor ConferencesMarch 28, 2024 | globenewswire.comPerspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial ResultsMarch 21, 2024 | markets.businessinsider.comBuy Rating Affirmed for Perspective Therapeutics Amid Clinical Success and Strategic PartnershipsMarch 19, 2024 | wsj.comPerspective Therapeutics Inc.April 30, 2024 | InvestorPlace (Ad)Elon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” March 18, 2024 | msn.comPerspective Therapeutics partners with Bristol Myers for its metastatic melanoma treatment studyMarch 18, 2024 | finance.yahoo.comPerspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic MelanomaMarch 12, 2024 | msn.comenGene Holdings GAAP EPS of -$0.46March 11, 2024 | finance.yahoo.comPerspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024March 7, 2024 | bizjournals.comPerspective Therapeutics raises $87 million on heels of big January roundMarch 4, 2024 | globenewswire.comPerspective Therapeutics Announces $87.4 Million Private PlacementFebruary 26, 2024 | finance.yahoo.comPerspective Therapeutics to Participate at Upcoming Investor ConferencesFebruary 13, 2024 | finance.yahoo.comPTC Therapeutics (PTCT) to Report Q4 Results: Wall Street Expects Earnings GrowthFebruary 12, 2024 | finance.yahoo.comPerspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 6, 2024 | msn.comPerspective Therapeutics Updates Corporate Presentation OnlineFebruary 1, 2024 | finance.yahoo.comPerspective Therapeutics Introduces “Pre-Targeting” Theranostic Technology PlatformFebruary 1, 2024 | finance.yahoo.comHeybike Will Soon Release Hero -- A Powerful All-Terrain E-bikeJanuary 29, 2024 | msn.comPerspective Therapeutics And 3 Other Stocks Under $2 Insiders Are BuyingJanuary 26, 2024 | msn.comPerspective gains as B. Riley sees over 100% upside on radiopharma prospectsJanuary 24, 2024 | bizjournals.comCancer treatment company Perspective Therapeutics raises $90MJanuary 22, 2024 | finance.yahoo.comPerspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private PlacementJanuary 18, 2024 | msn.comWhy Perspective Therapeutics (CATX) Shares Are FallingJanuary 18, 2024 | finance.yahoo.comPerspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private PlacementSee More Headlines Receive CATX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Perspective Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/30/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNYSEAMERICAN:CATX CUSIPN/A CIKN/A Webwww.isoray.com Phone(509) 375-1202Fax509-267-3670Employees116Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)-0.10 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,510,000.00 Net Margins-302.70% Pretax Margin-3,428.10% Return on Equity-46.44% Return on Assets-40.78% Debt Debt-to-Equity Ratio0.02 Current Ratio1.07 Quick Ratio1.07 Sales & Book Value Annual Sales$1.43 million Price / Sales673.11 Cash FlowN/A Price / Cash FlowN/A Book Value0.27 per share Price / Book6.07Miscellaneous Outstanding Shares586,920,000Free Float566,257,000Market Cap$962.55 million OptionableNot Optionable Beta1.56 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Johan M. Spoor (Age 52)CEO & Director Comp: $855.78kMr. Jonathan R. Hunt (Age 57)CFO & Co-Principal Financial Officer Comp: $944.35kDr. Markus Puhlmann M.B.A. (Age 57)M.D., Chief Medical Officer Comp: $633.14kMr. Shane CobbExecutive Vice President of OperationsMr. Mark J. Austin CPA (Age 37)VP of Finance, Corporate Controller, Co-Principal Financial, Principal Acc. Officer & Secretary Dr. Michael K. Schultz Ph.D.Chief Science OfficerMr. Andrew BrightExecutive Vice President of BrachytherapyMr. Amos Hedt BAPGradDip, Chief Business Strategy OfficerDr. Frances L. Johnson M.D.Chief Innovation OfficerMr. David Hauser Ph.D.Senior Vice President of Clinical OperationsMore ExecutivesKey CompetitorsMiMedx GroupNASDAQ:MDXGArtivionNYSE:AORTAtriCureNASDAQ:ATRCParagon 28NYSE:FNASilk Road MedicalNASDAQ:SILKView All CompetitorsInsiders & InstitutionsZWJ Investment Counsel Inc.Bought 22,000 shares on 4/26/2024Ownership: 0.004%Simplicity Wealth LLCBought 33,570 shares on 4/24/2024Ownership: 0.006%Lantheus Alpha Therapy, LlcBought 60,431,039 shares on 3/6/2024Total: $57.41 M ($0.95/share)Robert F Williamson IIIBought 25,266 shares on 1/29/2024Total: $16,170.24 ($0.64/share)Robert F Williamson IIIBought 22,134 shares on 1/25/2024Total: $10,845.66 ($0.49/share)View All Insider TransactionsView All Institutional Transactions CATX Stock Analysis - Frequently Asked Questions Should I buy or sell Perspective Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Perspective Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CATX shares. View CATX analyst ratings or view top-rated stocks. How have CATX shares performed in 2024? Perspective Therapeutics' stock was trading at 1.19 on January 1st, 2024. Since then, CATX stock has increased by 38.7% and is now trading at 1.65. View the best growth stocks for 2024 here. Are investors shorting Perspective Therapeutics? Perspective Therapeutics saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 10,430,000 shares, an increase of 28.9% from the March 31st total of 8,090,000 shares. Based on an average daily trading volume, of 4,090,000 shares, the days-to-cover ratio is currently 2.6 days. Currently, 2.2% of the company's stock are sold short. View Perspective Therapeutics' Short Interest. Who are Perspective Therapeutics' major shareholders? Perspective Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Simplicity Wealth LLC (0.01%) and ZWJ Investment Counsel Inc. (0.00%). Insiders that own company stock include Jonathan Robert Hunt, Lantheus Alpha Therapy, Llc, Markus Puhlmann and Robert F Williamson III. View institutional ownership trends. This page (NYSEAMERICAN:CATX) was last updated on 4/30/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportProtect Your Bank Account Before It’s Too LateWeiss RatingsHe Is Giving Away BitcoinCrypto Swap ProfitsElon Musk Secret Crypto Plot ExposedCrypto 101 MediaNvidia CEO Says It Will Be “the Next Revolution” Beyond AIBanyan Hill PublishingHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
